Aimee Donnellan has been a correspondent for Reuters since 2017. Her patch includes the pharmaceutical industry. Off the Scales is her first book. In brisk and breezy terms, it recounts the history and impact of the GLP-1 receptor agonist semaglutide (Ozempic). Perhaps because of her background in business journalism, Donnellan does not characterise the development of GLP-1 receptor agonists as a quixotic quest to improve public health. Her protagonists are motivated by all kinds of drivers, including the desire to hold onto their jobs, make money, and garner accolades.
Aimee Donnellan has been a correspondent for Reuters since 2017. Her patch includes the pharmaceutical industry. Off the Scales is her first book. In brisk and breezy terms, it recounts the history and impact of the GLP-1 receptor agonist semaglutide (Ozempic). Perhaps because of her background in business journalism, Donnellan does not characterise the development of GLP-1 receptor agonists as a quixotic quest to improve public health. Her protagonists are motivated by all kinds of drivers, including the desire to hold onto their jobs, make money, and garner accolades.